Kiyose-shi, Japan Clinical Trials

A listing of Kiyose-shi, Japan clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 24 clinical trials
Forxiga HF General Drug Use-Results Study

To capture safety when Forxiga is administered to patients with HF in clinical practice after launch.

Research site
 (8.5 away) Contact site
  • 19 Jun, 2022
  • +21 other locations
VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19

To provide more information on safety profile of VAXZEVRIA in Japanese subjects, specific drug use result study in subjects with underling disease at higher risk of worsening COVID-19 is planned as an additional pharmacovigilance plan. The present study aims to collect information on adverse drug reactions or COVID-19 infection after …

Research site
 (8.5 away) Contact site
  • 03 Jun, 2022
  • +5 other locations
Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia

The purpose of this study is to assess the safety and efficacy, including the incidence of thromboembolism, in renal anemia patients treated with roxadustat (EVRENZO® Tablets) in actual clinical settings.

Site JP00011
 (8.4 away) Contact site
  • 15 Jun, 2022
  • +46 other locations
A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

The purpose of this non-interventional study is to identify participants with urothelial cancer (UC) and selected fibroblast growth factor receptor (FGFR) aberrations through molecular testing of their archival tumor tissue.

growth factor
transitional cell carcinoma
Juntendo University Nerima Hospital
 (5.8 away) Contact site
  • 28 Jun, 2022
  • +152 other locations
Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

The objective of this study is to investigate the safety and effectiveness in routine clinical practice and actual clinical setting for all patients with rheumatoid arthritis (RA) treated with peficitinib.

Site JP00011
 (8.4 away) Contact site
  • 28 Jun, 2022
  • +46 other locations
Forxiga CKD Japan Post-Marketing Surveillance (PMS)

To capture safety when Forxige is administrated to CKD patients in the real world setting

Research site
 (8.5 away) Contact site
  • 30 Jun, 2022
  • +24 other locations
Survey Study for Velaglucerase Alfa (VPRIV) in Japan

The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or have been switched from another therapeutic agent for Gaucher disease.

velaglucerase alfa
 (3.5 away) Contact site
  • 12 Feb, 2022
  • +30 other locations
A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus

This study will assess the safety and effectiveness of Maviret (Glecaprevir plus Pibrentasvir (GLE/PIB)) in adolescent participants diagnosed with chronic hepatitis C (CHC) in a real world setting across clinical practice in Japan.

chronic hepatitis
Saitama Children's Medical Center /ID# 227633
 (9.3 away) Contact site
  • 23 Feb, 2022
  • +29 other locations
ADYNOVATE Drug Use-Results Survey

The purpose of this survey is to understand the following items in the actual clinical use of ADYNOVATE in patients: Unexpected adverse drug reactions Occurrence of adverse drug reactions in the actual clinical use Factors that may affect safety and efficacy Occurrence of Factor VIII inhibitor development in patients with …

coagulation factor
antihemophilic factor
factor viii inhibitor
Suginami-ku, Japan
 (6.5 away) Contact site
  • 10 Mar, 2022
  • +48 other locations
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients

This study is a single cohort, central registration system, all-case, open-label, multicenter observational study in patients using Mayzent for the indication of secondary progressive multiple sclerosis.

secondary progressive multiple sclerosis
Novartis Investigative Site
 (3.5 away) Contact site
  • 05 May, 2022
  • +166 other locations